ArticleOncoTargets and therapy2012
Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial.
Article in OncoTargets and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.Pharmacological research · 2018Review
- Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors.Advanced drug delivery reviews · 2017Review
- Brain metastasis in breast cancer: a comprehensive literature review.Journal of neuro-oncology · 2016Review
- Emerging strategies for treating brain metastases from breast cancer.Cancer cell · 2015Review
- Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.BioMed research international · 2015Article
- Brain metastasis: new opportunities to tackle therapeutic resistance.Molecular oncology · 2014Review
- Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy?International journal of molecular sciences · 2014Article
- Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer.Case reports in oncology · 2014Article
- Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).Biomedical reports · 2013Article
- Innovative therapeutic strategies in the treatment of brain metastases.International journal of molecular sciences · 2013Article
- Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases from breast cancer occur in 20%-40% of patients, and the frequency has increased over time. New radiosensitizers and cytotoxic or cytostatic agents, and innovative techniques of drug delivery are still under investigation.
methodsFive patients with brain metastases who did not respond to whole-brain radiotherapy and then received bevacizumab combined with paclitaxel were identified using our database of records between 2011 and 2012. The clinicopathological data and outcomes for these patients were then reviewed.
resultsThe median time to disease progression was 86 days. Of five patients, two (40%) achieved a partial response, two had stable disease, and one had progressive disease. In addition, one patient with brain metastases had ptosis and diplopia due to metastases of the right extraocular muscles. However, not only the brain metastases, but also the ptosis and diplopia began to disappear after 1 month of treatment. The most common treatment-related adverse events (all grades) were hypertension (60%), neuropathy (40%), and proteinuria (20%). No grade 3 toxicity was seen. No intracranial hemorrhage was observed.
conclusionWe present five patients with breast cancer and brain metastases, with benefits from systemic chemotherapy when combined with bevacizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.